Pharmacological activation of STAT1-GSDME pyroptotic circuitry reinforces epigenetic immunotherapy for hepatocellular carcinoma
2024/11/01 by Yalin Tu, Haoran Wu, Chengpeng Zhong +38 · 23 citations
Biochemistry, Genetics and Molecular Biology · Medicine · Immunology and Microbiology · #Inflammasome and immune disorders #Cancer Immunotherapy and Biomarkers #Immune cells in cancer
paper · pdf · doi:10.1136/gutjnl-2024-332281
Abstract
Background Genomic screening uncovered interferon-gamma (IFNγ) pathway defects in tumours refractory to immune checkpoint blockade (ICB). However, its non-mutational regulation and reversibility for therapeutic development remain less understood. Objective We aimed to identify ICB resistance-associated druggable histone deacetylases (HDACs) and develop a readily translatable combination approach for patients with hepatocellular carcinoma (HCC). Design We correlated the prognostic outcomes of HCC patients from a pembrolizumab trial ( NCT03419481 ) with tumourous cell expressions of all HDAC isoforms by single-cell RNA sequencing. We investigated the therapeutic efficacy and mechanism of action of selective HDAC inhibition in 4 ICB-resistant orthotopic and spontaneous models using immune profiling, single-cell multiomics and chromatin immunoprecipitation-sequencing and verified by genetic modulations and co-culture systems. Results HCC patients showing higher HDAC1 / 2 / 3 expressions exhibited deficient IFNγ signalling and poorer survival on ICB therapy. Transient treatment of a selective class-I HDAC inhibitor CXD101 resensitised HDAC1/2/3 high tumours to ICB therapies, resulting in CD8 + T cell-dependent antitumour and memory T cell responses. Mechanistically, CXD101 synergised with ICB to stimulate STAT1-driven antitumour immunity through enhanced chromatin accessibility and H3K27 hyperacetylation of IFNγ-responsive genes. Intratumoural recruitment of IFNγ + GZMB + cytotoxic lymphocytes further promoted cleavage of CXD101-induced Gasdermin E (GSDME) to trigger pyroptosis in a STAT1-dependent manner. Notably, deletion of GSDME mimicked STAT1 knockout in abolishing the antitumour efficacy and survival benefit of CXD101-ICB combination therapy by thwarting both pyroptotic and IFNγ responses. Conclusion Our immunoepigenetic strategy harnesses IFNγ-mediated network to augment the cancer-immunity cycle, revealing a self-reinforcing STAT1-GSDME pyroptotic circuitry as the mechanistic basis for an ongoing phase-II trial to tackle ICB resistance ( NCT05873244 ).
Cited by
- The role of pyroptosis in cancer: key components and therapeutic potential. [europepmc]
- Overcoming immunotherapy resistance in hepatocellular carcinoma by targeting myeloid IL-8/CXCR2 signaling. [europepmc]
- The epigenetic basis of hepatocellular carcinoma - mechanisms and potential directions for biomarkers and therapeutics. [europepmc]
- HDAC1 Mediates Immunosuppression of the Tumor Microenvironment in Non-Small Cell Lung Cancer. [europepmc]
- Expression landscape of epigenetic genes in human hepatocellular carcinoma. [europepmc]
- Dual function of Gasdermin E: pyroptosis-mediated pan-cancer suppression versus HCC-specific oncogenic activity. [europepmc]
- Targeting super-enhancers in liver cancer: from pathogenic mechanisms to clinical applications. [europepmc]
- Application of Immune Checkpoint Inhibitors in Cancer. [europepmc]
- STAT1β modulates the tumor immune microenvironment to improve prognosis in ovarian cancer: a comprehensive study of transcriptional and protein expression differences. [europepmc]
- The HDAC inhibitor romidepsin renders liver cancer vulnerable to RTK targeting and immunologically active. [europepmc]
- ZEB1 promotes chemoimmunotherapy resistance in pancreatic cancer models by downregulating chromatin acetylation of CXCL16. [europepmc]
- Epigenetic orchestration of cancer-immune dynamics: mechanisms, technologies, and clinical advancements. [europepmc]
- Epigenetic Regulation Through Histone Deacetylation: Implications and Therapeutic Potential in Hepatocellular Carcinoma. [europepmc]
- Debates and progress in the management of intermediate-stage (BCLC stage B) hepatocellular carcinoma. [europepmc]
- Combination immunotherapy in hepatocellular carcinoma: synergies among immune checkpoints, TKIs, and chemotherapy. [europepmc]
- Exploring the prognostic value of T cell exhaustion and mitochondrial dysfunction related genes in breast cancer through bioinformatics analysis and RT-qPCR validation. [europepmc]
- Targeting ferroptosis, pyroptosis and necroptosis for cancer immunotherapy in melanoma: mechanistic insights and clinical perspectives. [europepmc]
- The molecular mechanisms of pyroptosis and its implications in tumor immunotherapy. [europepmc]
- Pan-cancer analysis reveals HDAC1 as a key regulator of immune infiltration and T cell exhaustion. [europepmc]
- Targeting G9a Exerts Pleiotropic Suppression in Triple-Negative Breast Cancer Cells: Cooperatively Inducing Pyroptosis and Apoptosis. [europepmc]
- Overcoming MDSC-Mediated Immunosuppression in Hepatocellular Carcinoma: From Mechanisms to Novel Immunotherapeutic Approaches. [europepmc]
- Chromatin Accessibility in Cancer: Biological Functions, Mechanisms, Therapeutic Potential, and Future Directions. [europepmc]
- Overcoming immune resistance in hepatocellular carcinoma: insights into mechanisms, predictive factors, and interventional strategies. [europepmc]
Related